Breaking News
FONT-SIZE Plus   Neg
Share SHARE

KineMed And Pfizer Extend Collaboration On Type II Diabetes - Quick Facts

RELATED NEWS
Trade PFE now with 

KineMed Inc. announced the renewal of a non-exclusive research collaboration with Pfizer Inc. (PFE: Quote) for the advancement of novel approaches in metabolic disease, in particular Type II diabetes.

KineMed stated that the collaboration employs its novel dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.

"This platform has been useful in accelerating advancement and de-risking compounds in Type II diabetes. We look forward to continuing our work with Pfizer on their compounds in preclinical and clinical trials," said Marc Hellerstein, President, Chief Science Officer and Co-founder at KineMed.

Click here to receive FREE breaking news email alerts for Pfizer Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The U.K. economy grew at a slower pace in the third quarter in the face of rising uncertainty stemming from global economic conditions, preliminary estimates from the Office for National Statistics Office showed Friday. Gross domestic product climbed 0.7 percent from the second quarter, when it grew 0.9 percent. German consumer climate is set to improve slightly in November, ending the downward trend, as income expectations among households strengthened on the back of the strong labor market situation, survey data revealed Friday.The forward-looking consumer confidence index rose slightly to 8.5 in November from 8.4 in October. Software giant Microsoft Corp. said Thursday after the markets closed that its first quarter profit fell 13% from last year, hurt mainly by integration and restructuring costs even as revenue surged 25% thanks to strong sales of its gadgets and cloud-based products. However, the company's quarterly earnings per share came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.